HIV JournalView

Table of Contents

• Predicting Risk of Failure Among Those With Low-Level Viremia
• Screening for HIV Dementia Made Simple
• People Living (Large) With HIV/AIDS
• Antiretroviral Therapy and Insulin Resistance: It May Not Be What You Expect
• Valproic Acid, Anyone?
• References

Predicting Risk of Failure Among Those With Low-Level Viremia

Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ Jr. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr. September 1, 2005;40(1):34-40.

A wonderful prerogative of being an HIV JournalView author is that I can choose to highlight papers published by colleagues. Although this smacks of preferential treatment, if not outright pandering, it is also true that the papers I've chosen reflect the work of researchers whose integrity and methods I am extremely familiar with. Further, it's not like I am Oprah and with my review can ensure these authors a career of success and fame.

So, it is with no shame that I report on a paper by Sonia Napravnik et al, almost all of whom work within 25 feet of my office at the University of North Carolina (UNC). Their paper attempts to add to our understanding of what to do with patients who maintain a detectable but persistently low level of HIV viremia despite potent HIV therapy.

...

Want to read the rest of this article? To learn more about our audience, we're asking readers to register in order to receive full access to all of our materials. Please click here to begin your quick, free registration at The Body PRO.

If you're already registered with The Body PRO, please log in:

E-mail Address
Password
	Remember my login

Forgot your password?